Dr. Reddy's Laboratories’ arm, Ingenus Pharmaceuticals enter into license agreement

13 Jun 2024 Evaluate

Dr. Reddy's Laboratories’ wholly-owned subsidiary -- Dr Reddy's Laboratories Inc and Ingenus Pharmaceuticals, LLC have entered into license agreement. Subsequently, Dr Reddy's Laboratories Inc (Dr Reddy's USA) has licensed from Ingenus, the exclusive rights to commercialise Cyclophosphamide injection of strengths 500 mg/2.5mL; 1g/5mL; 2g/10mL in the US.

Under the in-licensing pact, Dr Reddy's USA will commercialise the Cyclophosphamide injection for the US market and will pay Ingenus 50 per cent of the calculated profit share and no other consideration is payable. 

The sales of the said Ingenus product as per the IQVIA for the past 12 months ended March 2024 was $51.8 million. The parties will enter into a commercial supply agreement pursuant to which Ingenus will supply the product to Dr Reddy's USA.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1342.45 16.45 (1.24%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.